TheraZyne is a research-driven biotechnology company specializing in AI-guided protein design and translational drug development.

We developed highly efficient “one-stop” antibody discovery and development platform for partnership with biotech and pharma.

Our proprietary platforms

• TZ-CATT™: Enhacing efficacy while minimizing off-target toxicity of antibody-based therapeutics
• TZ-mFc^LXL and TZ-dFc^LXL: Improving half-life of biologics

Our designed therapeutics assets

• TZ-Ab101: T cell engager (TCE) targets the KRAS(G12D) neoantigen for solid tumor therapy, advancing toward IND-enabling studies.
• TZ-GF101: A highly stable de novo Wnt-surrogate for organoid culture and hair regeneration.